Velagliflozin is an orally available sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor, with anti-diabetic activity. In Vitro Velagliflozin is an oral sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Velagliflozin (1 mg/kg; p.o.; single dose) increases cholesterol, albumin, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), and urinary glucose excretion, and decreases respiratory exchange ratio in cats . Velagliflozin (0.3 mg/kg; p.o.; once daily for 18 d) is well tolerated and can improve insulin disorders and prevent laminitis in ponies by reducing the high insulin response of dietary non-structural carbohydrates (NSC). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:SGLT2